Mersana Therapeutics (MRSN) Stock Price, News & Analysis

Company Overview

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $1.56 to $1.68
• 50-Day Range: $1.60 to $2.68
• 52-Week Range: $1.22 to $6.28
• Volume: 2.72 million shs
• Average Volume: 1.58 million shs
• Market Capitalization: $197.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Moderate Buy

Mersana Therapeutics Stock Analysis - MarketRank™

Mersana Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 126th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mersana Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mersana Therapeutics are expected to grow in the coming year, from ($0.61) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mersana Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mersana Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mersana Therapeutics has a P/B Ratio of 5.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.08% of the outstanding shares of Mersana Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Mersana Therapeutics has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Mersana Therapeutics has recently decreased by 7.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mersana Therapeutics does not currently pay a dividend.

Dividend Growth

Mersana Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.69

Percentage of Shares Shorted

7.08% of the outstanding shares of Mersana Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Mersana Therapeutics has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Mersana Therapeutics has recently decreased by 7.11%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.40

News Sentiment

Mersana Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Mersana Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for MRSN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

1 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mersana Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,440.00 in company stock.

Percentage Held by Insiders

11.80% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRSN Stock Analysis - Frequently Asked Questions

How have MRSN shares performed this year?

Mersana Therapeutics' stock was trading at $2.32 on January 1st, 2024. Since then, MRSN shares have decreased by 31.0% and is now trading at $1.60.
View the best growth stocks for 2024 here.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) issued its earnings results on Wednesday, November, 13th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08. Mersana Therapeutics's quarterly revenue was up 63.6% compared to the same quarter last year.

When did Mersana Therapeutics IPO?

Mersana Therapeutics (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' top institutional investors include State Street Corp (2.22%), Geode Capital Management LLC (1.97%), Verition Fund Management LLC (1.06%) and Acuta Capital Partners LLC (0.98%). Insiders that own company stock include Andrew A F Hack, Anna Protopapas, Martin H Jr Huber, Brian Deschuytner, Alejandra Carvajal, Mohan Bala, Ashish Mandelia, Arvin Yang, Tushar Misra and Timothy B Lowinger.
View institutional ownership trends.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Mersana Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Saia (SAIA), Rambus (RMBS), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/13/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRSN
• CUSIP: N/A
• CIK: 1442836
• Web: www.mersana.com
• Phone: (617) 498-0020
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +275.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-171,670,000.00
• Net Margins: -214.20%
• Pretax Margin: -212.99%
• Return on Equity: -401.37%
• Return on Assets: -38.61%

Debt

• Debt-to-Equity Ratio: 13.35
• Current Ratio: 2.35
• Quick Ratio: 2.35

Sales & Book Value

• Annual Sales: $36.85 million
• Price / Sales: 5.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 5.16

Miscellaneous

• Outstanding Shares: 123,530,000
• Free Float: 108,956,000
• Market Cap: $197.65 million
• Optionable: Optionable
• Beta: 1.40